Sympathetic Activation in Resistant Hypertension: Theory and Therapy

Seminars in Nephrology

Volumn 34, Issue 5, 2014, Pages 550-559

  Oliva, Raymond V ^a   Bakris, George L ^b  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Baroreceptor; Denervation; Hypertension; Resistance

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RESERPINE; SPIRONOLACTONE; SODIUM INTAKE;

ALCOHOL CONSUMPTION; BLOOD PRESSURE REGULATION; BODY MASS; BREAST TENDERNESS; CAROTID SINUS NERVE STIMULATOR; CAROTID SINUS PRESSORECEPTOR; CLINICAL TRIAL (TOPIC); DEVICE THERAPY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ELECTROSTIMULATION THERAPY; EVIDENCE BASED MEDICINE; FALSE ANEURYSM; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY DENERVATION; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MAXIMUM TOLERATED DOSE; MEDICAL SPECIALIST; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT REFERRAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRESCRIPTION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SODIUM INTAKE; SODIUM RESTRICTION; SYMPATHETIC TONE; TREATMENT RESPONSE; WEIGHT REDUCTION; ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; CORONARY VASOSPASM; DRUG RESISTANCE; HYPERTENSION; LIFESTYLE; PHYSIOLOGY; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; SYMPATHECTOMY;

ANIMALS; BAROREFLEX; BLOOD PRESSURE; CORONARY VASOSPASM; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; LIFE STYLE; PRESSORECEPTORS; SODIUM, DIETARY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84918514822     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.08.009     Document Type: Review

References (85)

1. Johnson A.D., Newton-Cheh C., Chasman D.I., et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension 2011, 57:903-910.
2. Tabara Y., Kohara K., Miki T. Hunting for genes for hypertension: the Millennium Genome Project for Hypertension. Hypertens Res 2012, 35:567-573.
3. Bolivar J.J. Essential hypertension: an approach to its etiology and neurogenic pathophysiology. Int J Hypertens 2013, 2013:547809.
4. Larsen R., Thorp A., Schlaich M. Regulation of the sympathetic nervous system by the kidney. Curr Opin Nephrol Hypertens 2014, 23:61-68.
5. Grassi G., Bertoli S., Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens 2012, 21:46-51.
6. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009, 54:690-697.
7. Kopp U.C. Renorenal reflexes: interaction between efferent and afferent renal nerve activity. Can J Physiol Pharmacol 1992, 70:750-758.
8. DiBona G.F., Kopp U.C. Neural control of renal function. Physiol Rev 1997, 77:75-197.
9. Kopp U.C., Cicha M.Z., Smith L.A. Impaired interaction between efferent and afferent renal nerve activity in SHR involves increased activation of alpha2-adrenoceptors. Hypertension 2011, 57:640-647.
10. Osborn J.W., Fink G.D., Sved A.F., Toney G.M., Raizada M.K. Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. Curr Hypertens Rep 2007, 9:228-235.
11. He F.J., MacGregor G.A. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004, 3:CD004937.
12. McBryde F.D., Guild S.J., Barrett C.J., Osborn J.W., Malpas S.C. Angiotensin II-based hypertension and the sympathetic nervous system: the role of dose and increased dietary salt in rabbits. Exp Physiol 2007, 92:831-840.
13. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010, 23:1052-1060.
14. Campese V.M., Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25:878-882.
15. Schlaich M.P., Socratous F., Hennebry S., et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009, 20:933-939.
16. Zhou Z., Zhu G., Hariri A.R., et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452:997-1001.
17. Grassi G. Phosducin-a candidate gene for stress-dependent hypertension. J Clin Invest 2009, 119:3515-3518.
18. Grassi G., Padmanabhan S., Menni C., et al. Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population. J Hypertens 2011, 29:1121-1127.
19. Greenfield J.R., Miller J.W., Keogh J.M., et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009, 360:44-52.
20. Bruno R.M., Sudano I., Ghiadoni L., Masi L., Taddei S. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension 2011, 57:79-84.
21. Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 2001, 19:1713-1716.
22. Raebel M.A., Ellis J.L., Carroll N.M., et al. Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med 2012, 27:57-64.
23. Jung O., Gechter J.L., Wunder C., et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013, 31:766-774.
24. Johnson A.G. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997, 17:277-289.
25. Conlin P.R., Moore T.J., Swartz S.L., et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000, 36:461-465.
26. Whelton A., White W.B., Bello A.E., Puma J.A., Fort J.G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959-963.
27. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
28. Sarafidis P.A., Bakris G.L. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749-1757.
29. Luft F.C., Weinberger M.H. Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on calcium antagonists. Hypertension 1988, 11:I229-I232.
30. Schafflhuber M., Volpi N., Dahlmann A., et al. Mobilization of osmotically inactive Na+ by growth and by dietary salt restriction in rats. Am J Physiol Renal Physiol 2007, 292:F1490-F1500.
31. Aguilera M.T., De la Sierra A., Coca A., Estruch R., Fernandez-Sola J., Urbano-Marquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 1999, 33:653-657.
32. Wildman R.P., Gu D., Muntner P., et al. Alcohol intake and hypertension subtypes in Chinese men. J Hypertens 2005, 23:737-743.
33. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., Cofield S., Calhoun D.A. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005, 18:805-812.
34. Hall J.E. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
35. Hall J.E., Kuo J.J., Da Silva A.A., de Paula R.B., Liu J., Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003, 12:195-200.
36. Taler S.J., Agarwal R., Bakris G.L., et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013, 62:201-213.
37. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014, 23:3-16.
38. Pisoni R., Ahmed M.I., Calhoun D.A. Characterization and treatment of resistant hypertension. Curr Cardiol Rep 2009, 11:407-413.
39. Aucott L., Rothnie H., McIntyre L., Thapa M., Waweru C., Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension 2009, 54:756-762.
40. Poobalan A.S., Aucott L.S., Smith W.C., Avenell A., Jung R., Broom J. Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev 2007, 8:503-513.
41. He F.J., Li J., Macgregor G.A. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ 2013, 346:f1325.
42. He F.J., Marciniak M., Visagie E., et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension 2009, 54:482-488.
43. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., Cofield S., Calhoun D.A. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005, 18:805-812.
44. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
45. Appel L.J., Miller E.R., Jee S.H., et al. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000, 102:852-857.
46. Moore T.J., Vollmer W.M., Appel L.J., et al. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension 1999, 34:472-477.
47. Svetkey L.P., Simons-Morton D., Vollmer W.M., et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 1999, 159:285-293.
48. Czarina A.M., Calhoun D.A. Treatment of resistant hypertension. Minerva Cardioangiol 2009, 57:787-812.
49. Graves J.W., Bloomfield R.L., Buckalew V.M. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989, 298:361-365.
50. Taler S.J. Treatment of resistant hypertension. Curr Hypertens Rep 2005, 7:323-329.
51. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311:507-520.
52. Krause T., Lovibond K., Caulfield M., McCormack T., Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011, 343:d4891.
53. Gradman A.H., Basile J.N., Carter B.L., Bakris G.L. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011, 13:146-154.
54. Gradman A.H., Basile J.N., Carter B.L., et al. Combination therapy in hypertension. J Am Soc Hypertens 2010, 4:90-98.
55. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
56. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
57. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221-229.
58. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159-1164.
59. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
60. Khosla N., Chua D.Y., Elliott W.J., Bakris G.L. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?. J Clin Hypertens (Greenwich) 2005, 7:354-356.
61. Staessen J.A., Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999, 282:539-546.
62. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
63. Oparil S. The ASCOT blood pressure lowering trial. Curr Hypertens Rep 2006, 8:229-231.
64. Chapman J.N., Kirby P., Caulfield M.C., Poulter N.R. Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens 2001, 15(Suppl 1):S23-S26.
65. Gheorghiade M., Khan S., Blair J.E., et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J 2009, 158:437-443.
66. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
67. Pitt B., Williams G., Remme W., et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79-87.
68. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., Lilledahl N.P. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
69. Calhoun D.A., Zaman M.A., Nishizaka M.K. Resistant hypertension. Curr Hypertens Rep 2002, 4:221-228.
70. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
71. Townsend R.R., DiPette D.J., Goodman R., et al. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990, 48:665-675.
72. Mahfoud F., Schlaich M., Kindermann I., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
73. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
74. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
75. Khan N.A., Herman R.J., Quinn R.R., et al. Renal denervation therapy for the treatment of resistant hypertension: a position statement by the Canadian Hypertension Education Program. Can J Cardiol 2014, 30:16-21.
76. Krum H., Schlaich M.P., Bohm M., et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014, 383:622-629.
77. Kandzari D.E., Bhatt D.L., Sobotka P.A., et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012, 35:528-535.
78. Briasoulis A., Bakris G. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention 2013, 9(Suppl R):R136-R139.
79. Lohmeier T.E., Hildebrandt D.A., Warren S., May P.J., Cunningham J.T. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol 2005, 288:R828-R836.
80. Kroon AA SJ, Scheffers I., Tordoir J., et al. Sustained blood pressure reduction by baroreflex activation therapy with a chronically implanted system: 4-year data of Rheos Debut-Ht study in patients with resistant hypertension. J Hypertens 2010, 28:e441.
81. Scheffers I.J., Kroon A.A., Schmidli J., et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010, 56:1254-1258.
82. Wustmann K., Kucera J.P., Scheffers I., et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009, 54:530-536.
83. Bisognano J.D., Bakris G., Nadim M.K., et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011, 58:765-773.
84. Bakris G.L., Nadim M.K., Haller H., Lovett E.G., Schafer J.E., Bisognano J.D. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012, 6:152-158.
85. US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: hypertension indication: drug labelling for cardiovascular outcome claims. Office of Communications, Division of Drug Information, 2011.